“It’s a huge game changer, been trying to do for 10 to 15 years, clarity and resolution are now tremendous,” Dr. James Gladstone, Mt. Sinai Health System said.
Using only a local anesthesia, Dr. Gladstone inserts the MI-Eye-2 into Liz’s knee. She was actually watching the same thing Dr. Gladstone was seeing.
It allows him to check and see what and where there’s damage inside the knee.
“Almost as good as O.R. scope, and in many ways better than MRI because it can give you direct visualization,” Dr. Gladstone said.
The Post spoke with Dr. James Gladstone, co-chief of sports medicine at the Icahn School of Medicine at Mount Sinai, who said three to five weeks is “very reasonable and may even [be optimistic]. If they come out and say he’ll take eight weeks, I wouldn’t be surprised.”
Even with Lin likely out past the trade deadline, Atkinson wants to see Brook-Lin together.
“They both believe that they can coexist together,” Atkinson said. “We haven’t said, ‘OK, we’re not going to see it.’ I understand the trade deadline and all that, but my mindset is I want to see them play when Jeremy’s back.”
Vericel Corporation announced the FDA approval of an autologous cellularized scaffold for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients.
The first FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds, each Maci (Vericel Corporation) implant is composed of a patient’s cells that are expanded and placed onto a bioresorbable porcine-derived collagen membrane that is implanted over the area where the defective or damaged tissue was removed, according to a press release.